Giuseppe Carlucci1, Brandon Carney2, Ahmad Sadique1, Axel Vansteene1, Jun Tang1, Thomas Reiner3. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA; Department of Chemistry, Hunter College and PhD Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10018, USA. 3. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA; Weill Cornell Medical College, New York, NY, 10065, USA. Electronic address: reinert@mskcc.org.
Abstract
RATIONALE: Ataxia telangiectasia and Rad3-related (ATR) threonine serine kinase is one of the key elements in orchestrating the DNA damage response (DDR). As such, inhibition of ATR can amplify the effects of chemo- and radiation-therapy, and several ATR inhibitors (ATRi) have already undergone clinical testing in cancer. For more accurate patient selection, monitoring and staging, real-time in vivo imaging of ATR could be invaluable; the development of appropriate imaging agents has remained a major challenge. METHODS: 3-amino-N-(4-[18F]phenyl)-6-(4-(methylsulfonyl)phenyl)pyrazine-2-carboxamide ([18F]-ATRi), a close analogue of Ve-821, (a clinical ATRi candidate), was readily accomplished similarly to already established synthetic procedures. Structurally, 18F was introduced at the 4-position of the aromatic ring of Ve-821 for generating a labeled ATR inhibitor. In vitro experiments were conducted in U251 MG glioblastoma cell lines and ex vivo biodistribution were performed in subcutaneous U251 MG xenograft bearing athymic nude mice following microPET imaging. RESULTS: [18F]-ATRi has a similar pharmacokinetic profile to that of Ve-821. Using an U251 MG glioblastoma mouse model, we evaluated the in vivo binding efficiency of [18F]-ATRi. Blood and tumor showed a statistically significant difference between mice injected with only the probe or following blocking experiment with Ve-821 (1.48±0.40%ID/g vs. 0.46±0.12%ID/g in tumor and 1.85±0.47%ID/g vs. 0.84±0.3%ID/g in blood respectively). CONCLUSIONS: [18F]-ATRi represents the first 18F positron emission tomography (PET) ATR imaging agent, and is designed on a low nanomolar and clinically relevant ATR inhibitor.
RATIONALE: Ataxia telangiectasia and Rad3-related (ATR) threonine serine kinase is one of the key elements in orchestrating the DNA damage response (DDR). As such, inhibition of ATR can amplify the effects of chemo- and radiation-therapy, and several ATR inhibitors (ATRi) have already undergone clinical testing in cancer. For more accurate patient selection, monitoring and staging, real-time in vivo imaging of ATR could be invaluable; the development of appropriate imaging agents has remained a major challenge. METHODS:3-amino-N-(4-[18F]phenyl)-6-(4-(methylsulfonyl)phenyl)pyrazine-2-carboxamide ([18F]-ATRi), a close analogue of Ve-821, (a clinical ATRi candidate), was readily accomplished similarly to already established synthetic procedures. Structurally, 18F was introduced at the 4-position of the aromatic ring of Ve-821 for generating a labeled ATR inhibitor. In vitro experiments were conducted in U251 MG glioblastoma cell lines and ex vivo biodistribution were performed in subcutaneous U251 MG xenograft bearing athymic nude mice following microPET imaging. RESULTS:[18F]-ATRi has a similar pharmacokinetic profile to that of Ve-821. Using an U251 MG glioblastomamouse model, we evaluated the in vivo binding efficiency of [18F]-ATRi. Blood and tumor showed a statistically significant difference between mice injected with only the probe or following blocking experiment with Ve-821 (1.48±0.40%ID/g vs. 0.46±0.12%ID/g in tumor and 1.85±0.47%ID/g vs. 0.84±0.3%ID/g in blood respectively). CONCLUSIONS:[18F]-ATRi represents the first 18F positron emission tomography (PET) ATR imaging agent, and is designed on a low nanomolar and clinically relevant ATR inhibitor.
Authors: J Adam Hendricks; Edmund J Keliher; Brett Marinelli; Thomas Reiner; Ralph Weissleder; Ralph Mazitschek Journal: J Med Chem Date: 2011-07-18 Impact factor: 7.446
Authors: Rozenn Jossé; Scott E Martin; Rajarshi Guha; Pinar Ormanoglu; Thomas D Pfister; Philip M Reaper; Christopher S Barnes; Julie Jones; Peter Charlton; John R Pollard; Joel Morris; James H Doroshow; Yves Pommier Journal: Cancer Res Date: 2014-09-30 Impact factor: 12.701
Authors: Brandon Carney; Giuseppe Carlucci; Beatriz Salinas; Valentina Di Gialleonardo; Susanne Kossatz; Axel Vansteene; Valerie A Longo; Alexander Bolaender; Gabriela Chiosis; Kayvan R Keshari; Wolfgang A Weber; Thomas Reiner Journal: Mol Imaging Biol Date: 2016-06 Impact factor: 3.488
Authors: Robin G Lerner; Stefan Grossauer; Banafsheh Kadkhodaei; Ian Meyers; Maxim Sidorov; Katharina Koeck; Rintaro Hashizume; Tomoko Ozawa; Joanna J Phillips; Mitchel S Berger; Theodore Nicolaides; C David James; Claudia K Petritsch Journal: Cancer Res Date: 2015-11-16 Impact factor: 12.701
Authors: Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde Journal: Med Res Rev Date: 2018-03-12 Impact factor: 12.944